Search Results
Your search for ,iII matches 9601 pages
Showing 2301 - 2350NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer
Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...
Nivolumab/Ipilimumab vs Dabrafenib/Trametinib With Switch at Disease Progression for Metastatic BRAF-Mutant Melanoma
As reported in the Journal of Clinical Oncology by Michael B. Atkins, MD, and colleagues, the phase III DREAMseq trial (ECOG-ACRIN EA6134) showed that first-line treatment with nivolumab plus ipilimumab followed at disease progression with dabrafenib and trametinib improved 2-year overall survival...
Decrease in Breast Cancer Mortality Rate Continues, but Gap Persists for Black Women: From American Cancer Society Report
Although breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die of the disease, despite a lower incidence, according to findings outlined in the American Cancer Society’s report Breast Cancer Statistics, 2022, and a companion study published by ...
ASCO Treatment Guidelines for HER2-Negative Metastatic Breast Cancer Updated to Reflect New Trastuzumab Deruxtecan Data
Just 1 month after the DESTINY-Breast04 data were presented at the 2022 ASCO Annual Meeting Plenary Session,1 an ASCO expert panel released updated guidance that endorses the adoption of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) into clinical practice for patients with...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
Expert Point of View: Jonathan Ledermann, MD
Jonathan Ledermann, MD, of UCL Cancer Institute University College London, was the formal discussant of both the phase III SOLO1 and PAOLA-1 trials. He was quite enthusiastic about SOLO1: “Perhaps, this is really cure we are seeing.” He also noted that overall survival is still immature and is...
First-Line Maintenance With Olaparib Improved Overall Survival in Subsets of Patients With Advanced Ovarian Cancer in Two Phase III Trials
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2022 Congress.1,2 In the SOLO1 trial,1 more...
TROPiCS-02: Sacituzumab Govitecan Improves Overall Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer
An overall survival benefit has now emerged for sacituzumab govitecan-hziy in women with previously treated, hormone receptor–positive/HER2-negative, locally recurrent, inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial.1 The...
5-Year Follow-up Supports Survival Benefit of Pembrolizumab Plus Chemotherapy in Squamous and Nonsquamous NSCLC
Pembrolizumab (anti–PD-1 therapy) plus chemotherapy continued to demonstrate a survival benefit and durable responses as first-line treatment of metastatic non–small cell lung cancer (NSCLC), according to the results of two phase III trials.1,2 Five-year overall survival was improved in both...
Expert Point of View: Alexander M.M. Eggermont, MD; Omid Hamid, MD; and James Larkin, PhD
The results of SWOG S18011 were met with enthusiasm by attendees at the Presidential Symposium of the European Society for Medical Oncology (ESMO) Congress 2022. The ASCO Post captured the thoughts of several melanoma experts, who had somewhat different ideas about the immediate clinical...
SWOG S1801: Addition of Neoadjuvant Pembrolizumab to Adjuvant Pembrolizumab Yields Benefits in High-Risk Resectable Melanoma
In resectable stage III to IV melanoma, three cycles of neoadjuvant pembrolizumab followed by adjuvant pembrolizumab was significantly more beneficial than adjuvant pembrolizumab alone, based on the results of the phase II SWOG S1801 trial presented in a Presidential Symposium at the European...
Expert Point of View: Hisashi Saji, MD
Abstract discussant Hisashi Saji, MD, Chair of Thoracic Surgery at St. Marianna University School of Medicine, Kawasaki, Japan, said that, based on two recently reported phase III studies, sublobar resection, including wedge resection and segmentectomy, must be considered as a standard of care for...
Sublobar Resection for Small, Early-Stage NSCLC: Establishing a New Standard of Care?
After a nearly 20-year wait, the results are finally in: sublobar surgery has been found to be noninferior to lobectomy and may be the new standard of care of patients with small, early-stage non–small cell lung cancer (NSCLC). Results of the phase III Alliance trial, presented at the International ...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Historical Housing Discrimination May Adversely Affect Contemporary Colon Cancer Care and Outcomes
Recent findings showed that historical housing discrimination may negatively affect contemporary care and outcomes for patients diagnosed with colon cancer, according to a study by Hussaini et al in the Journal of Clinical Oncology. The findings were also presented at the 2022 ASCO Quality Care...
Toxicity Outcomes With Stereotactic Ablative Radiotherapy for Patients With Up to Five Oligometastases
As reported in JAMA Oncology by Olson et al, the primary toxicity results of the phase II SABR-5 trial have shown a low rate of toxic effects with stereotactic ablative radiotherapy (SABR) for patients with up to five oligometastases. As stated by the investigators: “After the publication of the...
Chemotherapy for Children With Type II or III Pleuropulmonary Blastoma
In an analysis from the International PPB/DICER1 Registry reported in the Journal of Clinical Oncology, Schultz et al found that chemotherapy with IVADo (ifosfamide, vincristine, actinomycin-D, and doxorubicin) appeared to be associated with similar or improved outcomes vs historical controls among ...
Addition of PD-1 Inhibitor Serplulimab to Chemotherapy in the First-Line Treatment of Extensive-Stage SCLC
As reported in JAMA by Cheng et al, an interim analysis of the phase III ASTRUM-005 trial has shown that the addition of the PD-1 inhibitor serplulimab to chemotherapy improved overall survival in the first-line treatment of patients with extensive-stage small cell lung cancer (SCLC). Study ...
Adjuvant Nivolumab/Ipilimumab vs Nivolumab in Resected Stage IIIB–D or IV Melanoma
As reported in the Journal of Clinical Oncology by Jeffrey S. Weber, MD, PhD, and colleagues, the phase III CheckMate 915 trial showed no improvement in recurrence-free survival with adjuvant nivolumab/ipilimumab vs nivolumab in patients with resected stage IIIB–D or IV melanoma. Study Details In...
Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Trial Findings
Concurrent chemoradiation therapy followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 However, clinical trials have predetermined inclusion and exclusion criteria, and they evaluate...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were...
Highlights From the IASLC 2022 World Conference on Lung Cancer
Over the past few years, we have seen rapid and dramatic transformation in the therapeutic landscape of non–small cell lung cancer (NSCLC). We have had multiple new targeted therapies for newer targets (previously undruggable targets) and better diagnostic strategies to workup patients to realize...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, Professor in Thoracic Radiology at Royal Brompton and Harefield Hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, highlighted the increased risk of second primary tumors among current...
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
DART Trial: Concurrent Radiotherapy Plus Durvalumab Active in Older Patients With Locally Advanced Lung Cancer
Interim results of a phase II study have demonstrated the safety and feasibility of treating elderly and frail patients with locally advanced non–small cell lung cancer (NSCLC) with the monoclonal antibody durvalumab during and after radiation therapy, without chemotherapy. The results of a...
Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Patients With Metastatic NSCLC
The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). According to data...
Barbara Eichhorst, MD, on CLL: Venetoclax and Obinutuzumab With or Without Ibrutinib vs Chemoimmunotherapy
Barbara Eichhorst, MD, of the German CLL Study Group and the University of Cologne, discusses phase III findings from the GAIA/CLL13 trial, which showed that time-limited treatment with venetoclax, obinutzumab, and ibrutinib or venetoclax plus obinutzumab improved progression-free survival compared ...
John B.A.G. Haanen, MD, PhD, on Melanoma: Phase III Data on Treatment With Tumor-Infiltrating Lymphocytes vs Ipilimumab
John B.A.G. Haanen, MD, PhD, of The Netherlands Cancer Institute, discusses recent phase III findings, which show that tumor-infiltrating lymphocytes (TILs) improve progression-free survival compared with ipilimumab by 50% in patients with advanced melanoma after not responding to anti–PD-1...
DeFi Trial: Novel Gamma Secretase Inhibitor Halts Progression of Desmoid Tumors
Patients with rare desmoid tumors may finally have an effective treatment. A first-in-class gamma secretase inhibitor, nirogacestat, led to an improvement in progression-free survival in the phase III DeFi trial. The results were presented during the Presidential Symposium at the European Society...
Tissue vs ctDNA NGS for Detecting Actionable Alterations in Patients With Advanced Cancer
A large prospective analysis, published by Bayle et al in Annals of Oncology, evaluated differences between tissue and circulating tumor DNA (ctDNA) next-generation sequencing (NGS) with a large cancer gene panel. The investigators compared the impacts of both methods in terms of molecular tumor...
Inflammatory Markers and Clinical Decline After Adjuvant Chemotherapy in Older Women With Breast Cancer
As reported in the Journal of Clinical Oncology by Ji et al, the HOPE study (Hurria Older Patients [HOPE] with Breast Cancer Study) has shown that older women categorized as robust prior to adjuvant chemotherapy are at risk for clinical decline postchemotherapy, with high baseline levels of the...
2-Year Toxicity With Conventional IMRT vs Hypofractionated SBRT for Localized Prostate Cancer
As reported in The Lancet Oncology by Tree et al, an analysis from the phase III PACE-B trial has shown no difference in 2-year genitourinary or gastrointestinal toxicity with conventionally fractionated/moderately hypofractionated intensity-modulated radiotherapy (IMRT) vs highly hypofractionated...
Association of Breast Cancer Recurrence in Patients Achieving pCR With vs Without Residual DCIS After Neoadjuvant Chemotherapy
In a retrospective analysis from the neoadjuvant I-SPY2 trial reported in JAMA Surgery, Osdoit et al found that among patients with breast cancer achieving pathologic complete response (pCR), there were no significant differences in treatment outcomes according to the presence or absence of...
FDA Approves Biosimilar Bevacizumab-adcd for the Treatment of Six Types of Cancer
On September 28, the U.S. Food and Drug Administration (FDA) approved bevacizumab-adcd (Vegzelma), a biosimilar to bevacizumab (Avastin), for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic nonsquamous non–small cell lung cancer (NSCLC); recurrent...
Overall Survival With Maintenance Olaparib in Newly Diagnosed Patients With Advanced BRCA-Mutated Ovarian Cancer: 7-Year Follow-up
As reported in the Journal of Clinical Oncology by DiSilvestro et al, the 7-year follow-up of the phase III SOLO1/GOG 3004 trial showed a reduction in risk of death by almost half with maintenance olaparib vs placebo in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation,...
Exercise Therapy Across the Cancer Care Continuum
Guest Editor’s Note: Several studies have shown that regular physical activity helps to reduce the symptom burden and improve disease-related outcomes in patients with cancer. In this article, Jessica M. Scott, PhD, and Neil M. Iyengar, MD, summarize the current evidence surrounding exercise...
Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas
Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...
Axicabtagene Ciloleucel Improves Event-Free Survival vs Standard Care in Second-Line Treatment for Large B-Cell Lymphoma
As reported in The New England Journal of Medicine by Frederick L. Locke, MD, of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, Florida, and colleagues, the phase III ZUMA-7 trial in large B-cell lymphoma has shown improved event-free...
Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Metastatic NSCLC
The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). According to data...
Practice-Changing Studies, Important New Data, and More Clinical Oncology News From ESMO 2022, Paris
The European Society For Medical Oncology (ESMO) launched its annual congress, held September 9–13, 2022, just as this issue of The ASCO Post was going to press. Watch upcoming issues for comprehensive coverage of the live congress, following 2 years of virtual meetings and remote presentations due ...
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50%
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were...
Conditioning With Busulfan/Cyclophosphamide vs Total-Body Irradiation/Cyclophosphamide for B-Cell ALL
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Zhang et al found that conditioning with busulfan plus cyclophosphamide (BuCy) was noninferior to total-body irradiation plus cyclophosphamide (TBI-Cy) in 2-year overall survival among adult patients with standard-risk...
Precision Physical Activity Prescriptions May Improve Survival in Patients With Stage III Colon Cancer
Physical activity may be associated with improved outcomes for patients undergoing postoperative treatment for stage III colon cancer, according to findings from a new study out of Pennington Biomedical Research Center published by Brown et al in the Journal of Clinical Oncology. The study assessed ...
Nizar M. Tannir, MD, on RCC: Data on Bempegaldesleukin Plus Nivolumab vs Tyrosine Kinase Inhibitors in Untreated Disease
Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the PIVOT-09 study, which compared bempegaldesleukin plus nivolumab with the investigator’s choice of a tyrosine kinase inhibitor (either sunitinib or cabozantinib) in patients with...
Pafolacianine for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Janos L. Tanyi, MD, PhD, and colleagues found that use of pafolacianine infusion for intraoperative imaging improved the detection of lesions in patients with folate receptor–positive ovarian cancer, compared with using white light...
Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC
As reported in The Lancet Oncology by O’Brien et al, the second interim analysis of the phase III PEARLS/KEYNOTE-091 trial has shown significantly improved disease-free survival with adjuvant pembrolizumab vs placebo in patients with completely resected stage IB to IIIA non-small cell lung cancer...
Association of Distance to Treatment Facility, U.S. Region, and Insurance Status With Diagnosis of Advanced Colon Cancer
In a National Cancer Database analysis reported in JAMA Network Open, Brand et al found that patients with colon cancer who lived farther from their treatment facility and those with no insurance or Medicaid alone were more likely to present with advanced-stage disease. As stated by the...
Neoadjuvant Endocrine Therapy May Elicit Differential Responses in Black vs White Women With Breast Cancer
Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than White women if treated at an earlier disease stage, but less likely to benefit than White women if treated at a later disease stage, according to results presented at the 15th American...
'Real-World' Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Findings
Concurrent chemoradiation followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 But clinical trials have predetermined inclusion and exclusion criteria, and they evaluate selective...
